Intended for healthcare professionals

  1. Research
  2. Restoring Study 329:...
  3. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
CCBYNC Open access
Research

Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4320 (Published 16 September 2015) Cite this as: BMJ 2015;351:h4320

Data supplement

  • Data supplement

    Files in this Data Supplement:

    • Appendix 1 - RIAT Audit Record
    • Appendix 2 - Supplementary tables
    • Appendix 3 - Supplementary information on suicidal and self-injurious behaviours in Study 329

Related articles

EditorialLiberating the data from clinical trials
FeatureNo correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsib

See more

Cited by...

  • Status, use and impact of sharing individual participant data from clinical trials: a scoping review
  • Achieving greater independence from commercial influence in research
  • Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
  • Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study
  • Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?
  • Children of the Cure: Missing Data, Lost Lives and Antidepressants, by David Healy, Joanna Le Noury, and Julie Wood
  • Defending transparency at European drug regulator
  • The "pharmaceuticalisation" of life
  • Critical appraisal of adverse effects reporting in the 'Treatment for Adolescents With Depression Study (TADS)
  • Best Practices in Data Analysis and Sharing in Neuroimaging using MRI
  • Research integrity and the law that never was
  • When to include clinical study reports and regulatory documents in systematic reviews
  • Why data sharing is important for children
  • EMA scales back transparency initiatives because of workload
  • Problematic Advice From Suicide Prevention Experts
  • Restoring biomedical literature with RIAT
  • Redefining the 'E in EBM
  • Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine
  • Composition of Canadian Pain Society guideline development group?
  • Authors Response
  • Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature
  • Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports
  • Update on Pediatric Overuse
  • Antidepressant use and violent crimes among young people: a longitudinal examination of the Finnish 1987 birth cohort
  • Is this trial misreported? Truth seeking in the burgeoning age of trial transparency
  • Beyond open data: realising the health benefits of sharing data
  • Ghostwriting: the importance of definition and its place in contemporary drug marketing
  • Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials
  • Superiority trials: statistical trickery or mass blindness?
  • 2015: a year in review
  • Retraction of biased journal articles
  • Paroxetine and Study 329: what we already knew and when
  • Authors' reply to Sasich and Linden
  • Open access as a requirement for research ethics committee approval
  • Restoring Study 329: results differ with the adverse event classification system used
  • Liberating the data from clinical trials
  • No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility
Back to top